Actelion retained at neutral by Merrill

Actelion was kept at neutral by Merrill Lynch analyst Whittaker and value at CHF 123 per share. Merrill looks to events in the next few months that may underscore the competitive threat to Tracleer sales, including potential approval of Thelin for PAH. The analyst continues to anticipate ambrisentan to be the number one drug prescribed by physicians for new PAH patients by 2010. Shares of the Allschwil, Switzerland, biopharmaceutical company were up CHF 4.50, or 4.16%, at CHF 112.60 on volume of 335,583 shares versus the three-month running average of 175,878 shares. (Swiss: ATLN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.